JPWO2023121975A5 - - Google Patents

Info

Publication number
JPWO2023121975A5
JPWO2023121975A5 JP2024536420A JP2024536420A JPWO2023121975A5 JP WO2023121975 A5 JPWO2023121975 A5 JP WO2023121975A5 JP 2024536420 A JP2024536420 A JP 2024536420A JP 2024536420 A JP2024536420 A JP 2024536420A JP WO2023121975 A5 JPWO2023121975 A5 JP WO2023121975A5
Authority
JP
Japan
Prior art keywords
cell
optionally substituted
compound
absent
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024536420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501731A5 (https=
JP2025501731A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/053209 external-priority patent/WO2023121975A1/en
Publication of JP2025501731A publication Critical patent/JP2025501731A/ja
Publication of JPWO2023121975A5 publication Critical patent/JPWO2023121975A5/ja
Publication of JP2025501731A5 publication Critical patent/JP2025501731A5/ja
Pending legal-status Critical Current

Links

JP2024536420A 2021-12-20 2022-12-16 イオン化可能なアミン脂質及び脂質ナノ粒子 Pending JP2025501731A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163291639P 2021-12-20 2021-12-20
US63/291,639 2021-12-20
US202263354627P 2022-06-22 2022-06-22
US63/354,627 2022-06-22
PCT/US2022/053209 WO2023121975A1 (en) 2021-12-20 2022-12-16 Ionizable amine lipids and lipid nanoparticles

Publications (3)

Publication Number Publication Date
JP2025501731A JP2025501731A (ja) 2025-01-23
JPWO2023121975A5 true JPWO2023121975A5 (https=) 2025-12-23
JP2025501731A5 JP2025501731A5 (https=) 2025-12-23

Family

ID=85157159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024536420A Pending JP2025501731A (ja) 2021-12-20 2022-12-16 イオン化可能なアミン脂質及び脂質ナノ粒子

Country Status (6)

Country Link
US (1) US20240335385A1 (https=)
EP (1) EP4452935A1 (https=)
JP (1) JP2025501731A (https=)
AU (1) AU2022418511A1 (https=)
CA (1) CA3241488A1 (https=)
WO (1) WO2023121975A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12569438B2 (en) 2019-07-29 2026-03-10 Georgia Tech Research Corporation Nanomaterials containing constrained lipids and uses thereof
US12435035B2 (en) 2020-01-09 2025-10-07 Guide Therapeutics, Llc Nanomaterials
IL303845A (en) 2021-01-20 2023-08-01 Beam Therapeutics Inc Nanomaterials include a degradable property
KR20230131863A (ko) 2021-01-20 2023-09-14 빔 테라퓨틱스, 인크. 나노물질
US20260035338A1 (en) * 2022-10-13 2026-02-05 Shenzhen Shenxin Biotechnology Co., Ltd. Amino lipid compound and lipid nanoparticle for delivering bioactive ingredient
WO2025189064A1 (en) 2024-03-08 2025-09-12 Genzyme Corporation Lipid nanoparticles
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030083272A1 (en) 1997-09-19 2003-05-01 Lahive & Cockfield, Llp Sense mrna therapy
AU2009238175C1 (en) 2008-04-15 2023-11-30 Arbutus Biopharma Corporation Novel lipid formulations for nucleic acid delivery
SG186085A1 (en) * 2010-06-03 2013-01-30 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
EP2788006B1 (en) * 2011-12-07 2026-01-07 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
EP4019506A1 (en) * 2013-12-19 2022-06-29 Novartis AG Lipids and lipid compositions for the delivery of active agents
EP4286012A3 (en) 2015-09-17 2024-05-29 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
JP7109784B2 (ja) 2015-10-23 2022-08-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 遺伝子編集のための進化したCas9蛋白質
KR102547316B1 (ko) 2016-08-03 2023-06-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
MX2020006843A (es) * 2017-12-27 2020-09-03 Takeda Pharmaceuticals Co Nanoparticula de lipido que contiene acido nucleico y uso de la misma.
KR20210139265A (ko) 2019-02-13 2021-11-22 빔 테라퓨틱스, 인크. 표적 서열에서 핵염기를 변형하기 위한 아데노신 데아미나제 염기 편집기 및 이의 사용 방법
WO2020219876A1 (en) * 2019-04-25 2020-10-29 Intellia Therapeutics, Inc. Ionizable amine lipids and lipid nanoparticles
WO2020246581A1 (ja) * 2019-06-07 2020-12-10 富士フイルム株式会社 脂質組成物

Similar Documents

Publication Publication Date Title
JP7075669B2 (ja) 核酸送達用カチオン性脂質及びその調製物
JPWO2022140252A5 (https=)
JP2024542188A (ja) 新規イオン化可能な脂質および脂質ナノ粒子ならびにそれらを使用する方法
EA033966B1 (ru) Стереохимически обогащенные композиции для доставки нуклеиновых кислот
CN111417621A (zh) 阳离子脂质
JPWO2023121975A5 (https=)
CN120225500A (zh) 用于活性物质递送的脂质化合物及组合物
JPWO2023121971A5 (https=)
JPWO2022159475A5 (https=)
JPWO2022159472A5 (https=)
CN115745788A (zh) 一种可电离脂质化合物及其制备方法和应用
JPWO2022159463A5 (https=)
JPWO2022159421A5 (https=)
CN120359207A (zh) 一种阳离子脂质材料的制备及应用
WO2024078614A1 (zh) 用于递送生物活性成分的氨基脂质化合物和脂质纳米颗粒
JPWO2022140238A5 (https=)
WO2023160702A1 (zh) 氨基脂质化合物、其制备方法、组合物和应用
KR102320650B1 (ko) 혈뇌장벽 투과능을 가지는 펩티드 핵산 복합체 및 이를 포함하는 조성물
WO2021117770A1 (ja) 医薬組成物及び処置剤
CN120152962A (zh) 脂质纳米粒子
TW202532053A (zh) 用於遞送治療劑的組成物和化合物
WO2025055936A1 (zh) 局部递送药物的材料及其应用
WO2025036455A1 (zh) 药物递送材料及其应用
WO2025194120A1 (en) Zwitterionic polymer functionalized lipid nanoparticles for delivery of nucleic acids
CN120247835A (zh) 阳离子脂质化合物、其制备方法、包含其的组合物及应用